AZ: US Federal Circuit 'Flagrantly Violated Precedent' On Symbicort
Federal Circuit Had Last Month Vacated Stipulated Judgment Of Infringement
The US Court of Appeals for the Federal Circuit has “abandoned the basic principles of significant figures that have long been recognized by this court,” AstraZeneca argues, as part of its petition to have reheard a recent verdict favoring Mylan on the originator’s Symbicort IP.
